Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 5/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | BLM | P54132 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16691724 | 0.92 | MTNR1A (0.45) | CHRM1CHRM4CHRM5CHRM3CHRM2 | |
| SCHEMBL8294603 | 0.82 | FABP7 (0.46) | CHRM1CHRM4CHRM5CHRM3CHRM2 | |
| SCHEMBL29697543 | 0.80 | MTNR1A (0.49) | CHRM1CHRM4CHRM5CHRM3LMNA | |
| SCHEMBL14838283 | 0.79 | IDO1 (0.51) | CHRM4PIN1TSHR | |
| SCHEMBL754296 | 0.77 | — | — | |
| SCHEMBL29697547 | 0.76 | MTNR1A (0.53) | CHRM1CHRM4CHRM5CHRM3MEN1 | |
| SCHEMBL2419961 | 0.73 | CYP19A1 (0.50) | CHRM1CHRM4CHRM5CHRM3CHRM2 | |
| SCHEMBL7915891 | 0.73 | CYP19A1 (0.46) | CHRM1CHRM4CHRM5CHRM3CHRM2 | |
| SCHEMBL30612403 | 0.72 | MTNR1A (0.53) | CHRM4KMT2AMTNR1AMTNR1BTSHR | |
| SCHEMBL6668382 | 0.72 | PDPK1 (0.44) | CYP2D6CYP2C9PIN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101573-A1 | MACROCYCLIC K-RAS G12C INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2024-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101573-A1 | MACROCYCLIC K-RAS G12C INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | KRAS, NRAS, HRAS | CHRM1 4851/4885CHRM4 4850/4885CHRM5 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.